A Randomized, Double-Blind, Single Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3475766
Latest Information Update: 04 Nov 2021
At a glance
- Drugs LY 3475766 (Primary) ; LY 3475766 (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 27 Apr 2021 Status changed from active, no longer recruiting to completed.
- 03 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 02 Dec 2020 Planned End Date changed from 22 Mar 2021 to 21 Apr 2021.